» Articles » PMID: 16401812

C-reactive Protein is a Marker for Human Immunodeficiency Virus Disease Progression

Overview
Journal Arch Intern Med
Specialty General Medicine
Date 2006 Jan 13
PMID 16401812
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Limited data on acute-phase C-reactive protein (CRP) levels in human immunodeficiency virus (HIV) infection exist.

Methods: We obtained a single measurement of CRP from 513 HIV-infected men in the Multicenter AIDS Cohort Study to examine the association between CRP and immune suppression and progression to AIDS. We estimated changes in CRP during the course of HIV infection in 81 of these individuals using specimens collected from October 1, 1984, to December 31, 1996.

Results: The cross-sectional associations between log(10) CRP were correlated inversely with CD4 lymphocyte counts (r=-0.17; P<.001) and directly with log10 HIV RNA levels (r=0.20; P<.001). Levels of CRP of more than 2.3 mg/L were associated with a decreased time to the development of AIDS (relative time to AIDS, 0.36; P<.001) compared with individuals with CRP levels of 1.2 mg/L or less, which remained significant after adjustment for CD4 lymphocyte counts and HIV RNA and hemoglobin concentrations. Levels of CRP significantly increased over time with mean slopes of 8.5% (95% confidence interval, 4.9%-12.2%) and 4.5% (95% confidence interval CI, 2.1%-6.9%) per year for individuals with and without progression to AIDS, respectively. Individuals had a geometric mean CRP level of 2.5 mg/L in the 6-month interval before progression to AIDS, which was an increase from a nadir of 1.0 mg/L at 6.5 years before progression to AIDS.

Conclusions: Levels of CRP were associated with HIV disease progression independent of CD4 lymphocyte counts and HIV RNA levels. In addition, regardless of progression to AIDS, HIV-infected individuals had a significant increase in CRP over time. This may have implications for cardiovascular disease among HIV-infected individuals.

Citing Articles

Atherogenic Index of Plasma and High-Sensitivity C-Reactive Protein Levels Among People Living With HIV on Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy and Their Correlations to CD4 Cell Counts.

Waritu N, Usure R, Adema B, Wakeyo M, Jemal M AIDS Res Treat. 2025; 2025:1468678.

PMID: 39834358 PMC: 11745559. DOI: 10.1155/arat/1468678.


Elevated Inflammation Associated with Markers of Neutrophil Function and Gastrointestinal Disruption in Pilot Study of Co-Infection of ART-Treated SIVmac239+ Rhesus Macaques.

Nemphos S, Green H, Prusak J, Fell S, Goff K, Varnado M Viruses. 2024; 16(7.

PMID: 39066199 PMC: 11281461. DOI: 10.3390/v16071036.


A Two-Faced Gut Microbiome: Butyrogenic and Proinflammatory Bacteria Predominate in the Intestinal Milieu of People Living with HIV from Western Mexico.

Baltazar-Diaz T, Andrade-Villanueva J, Sanchez-Alvarez P, Amador-Lara F, Holguin-Aguirre T, Sanchez-Reyes K Int J Mol Sci. 2024; 25(9).

PMID: 38732048 PMC: 11084381. DOI: 10.3390/ijms25094830.


Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV.

Ngare I, Tan T, Toyoda M, Kuwata T, Takahama S, Nakashima E Viruses. 2024; 16(4).

PMID: 38675897 PMC: 11053946. DOI: 10.3390/v16040555.


Weight Gain and Increased Body Mass Index in Patients with Hepatitis C after Eradication Using Direct-Acting Antiviral Therapy in Taiwan.

Chen C, Hsieh Y, Chen W, Shen C, Wei K, Chang K Diagnostics (Basel). 2024; 14(2).

PMID: 38275460 PMC: 10814234. DOI: 10.3390/diagnostics14020213.